Severe persistent visual field constriction associated with vigabatrin

BMJ

Volumn 316, Issue 7126, 1998, Pages 232-233

  Harding, G F A ^a   Mackenzie, Rod ^b   Klistorner, Alexander ^c  

^a ASTON UNIVERSITY   (United Kingdom)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

CLINICAL PRACTICE; DATA BASE; ELECTRORETINOGRAM; EPILEPSY; HUMAN; LETTER; PERIMETRY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VISUAL FIELD DEFECT;

ANTICONVULSANTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RISK ASSESSMENT; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 0032539375     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7126.232     Document Type: Letter

References (5)

1. Faedda MT, Giallondardo AT, Marchetti A, Manfredi M. Vigabatrin therapy for resistant partial epilepsy [in Italian]. Giornale Neuropsicofarmacol 1993; 15(3):105-8.
2. Eke T, Talbot JF, Lawden MC. BMJ 1997; 314: 180-1.
3. Harding G, Wild J, Robertson K, Edson E, Barber C, Lawden M, et al. Electrooculography, ERGs, multi-focal ERGs and VEPs in epileptic patients showing visual field disorders. Electroenceph Clin Neurophysiol 1997; 103: 96. (P-14-13.)
4. Martinez C, Noack H. The risk of visual field defects and the use of vigabatrin. Denham: Hoechst Marion Roussel, 1997. (Internal report.)
5. Eke T, Talbot JF, Lawden MC. BMJ 1997; 314: 180-1.